Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 25, Issue 4, Pages 793-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2011.04.010
Keywords
Renal cell carcinoma; PD-1 blockade; Immunotherapy
Categories
Funding
- DF/HCC Renal Cancer [P50 CA101942-01]
Ask authors/readers for more resources
Although several cytokines have shown antitumor activity in renal cell carcinoma (RCC), the most consistent results have been reported with interleukin-2 (IL-2) and interferon (IFN). Recent insights into how the immune response to a tumor is regulated hold the promise of allowing patients to obtain a durable response to immunotherapy, perhaps without the significant toxicity associated with conventional approaches. This review describes how improvements in patient selection, combination therapy, and investigational agents might expand and better define the role of immunotherapy in metastatic RCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available